Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
1
2-((5-bromo-6-oxo-1-phenyl-1,6-dihydropyridazin-4-yl)amino)acetamide
Homo sapiens;
-
IC50 above 1.0 mM, in 40 mM Tris pH 7.5, 20 mM MgCl2, 0.1 mg/ml bovine serum albumin, at 30°C
0.5
2-(5-bromo-6-oxo-1-phenyl-1,6-dihydropyridazin-4-yl)-1,2,3,4-tetrahydroisoquinoline-5-carbonitrile
Homo sapiens;
-
IC50 above 0.5 mM,in 40 mM Tris pH 7.5, 20 mM MgCl2, 0.1 mg/ml bovine serum albumin, at 30°C
0.026
3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one
Homo sapiens;
-
in 40 mM Tris pH 7.5, 20 mM MgCl2, 0.1 mg/ml bovine serum albumin, at 30°C
0.0084
4-(4-(4-acetyl-5-methyl-1H-1,2,3-triazol-1-yl)-5-bromo-6-oxopyridazin-1(6H)-yl)benzonitrile
Homo sapiens;
-
in 40 mM Tris pH 7.5, 20 mM MgCl2, 0.1 mg/ml bovine serum albumin, at 30°C
1
4-bromo-2-phenyl-5-(((tetrahydrofuran-2-yl)methyl)amino)pyridazin-3(2H)-one
Homo sapiens;
-
IC50 above 1.0 mM, in 40 mM Tris pH 7.5, 20 mM MgCl2, 0.1 mg/ml bovine serum albumin, at 30°C
1
4-bromo-2-phenyl-5-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pyridazin-3(2H)-one
Homo sapiens;
-
IC50 above 1.0 mM, in 40 mM Tris pH 7.5, 20 mM MgCl2, 0.1 mg/ml bovine serum albumin, at 30°C
1
4-bromo-5-morpholino-2-phenylpyridazin-3(2H)-one
Homo sapiens;
-
IC50 above 1.0 mM,in 40 mM Tris pH 7.5, 20 mM MgCl2, 0.1 mg/ml bovine serum albumin, at 30°C
0.0034
5-(4-acetyl-5-methyl-1H-1,2,3-triazol-1-yl)-2-benzyl-4-bromopyridazin-3(2H)-one
Homo sapiens;
-
in 40 mM Tris pH 7.5, 20 mM MgCl2, 0.1 mg/ml bovine serum albumin, at 30°C
10
5-(4-acetyl-5-methyl-1H-1,2,3-triazol-1-yl)-2-benzylpyridazin-3(2H)-one
Homo sapiens;
-
IC50 above 10 mM, in 40 mM Tris pH 7.5, 20 mM MgCl2, 0.1 mg/ml bovine serum albumin, at 30°C
0.011
5-(4-acetyl-5-methyl-1H-1,2,3-triazol-1-yl)-4-bromo-2-(3-phenylpropyl)pyridazin-3(2H)-one
Homo sapiens;
-
in 40 mM Tris pH 7.5, 20 mM MgCl2, 0.1 mg/ml bovine serum albumin, at 30°C
0.5
5-(4-acetyl-5-methyl-1H-1,2,3-triazol-1-yl)-4-bromo-2-(4-((2-(dimethylamino)ethyl)-amino)benzyl)pyridazin-3(2H)-one
Homo sapiens;
-
IC50 above 0.5 mM, in 40 mM Tris pH 7.5, 20 mM MgCl2, 0.1 mg/ml bovine serum albumin, at 30°C
0.0091
5-(4-acetyl-5-methyl-1H-1,2,3-triazol-1-yl)-4-bromo-2-(4-(trifluoromethoxy)phenyl)-pyridazin-3(2H)-one
Homo sapiens;
-
in 40 mM Tris pH 7.5, 20 mM MgCl2, 0.1 mg/ml bovine serum albumin, at 30°C
0.007
5-(4-acetyl-5-methyl-1H-1,2,3-triazol-1-yl)-4-bromo-2-(4-chlorophenyl)pyridazin-3(2H)-one
Homo sapiens;
-
in 40 mM Tris pH 7.5, 20 mM MgCl2, 0.1 mg/ml bovine serum albumin, at 30°C
0.0087
5-(4-acetyl-5-methyl-1H-1,2,3-triazol-1-yl)-4-bromo-2-(4-iodobenzyl)pyridazin-3(2H)-one
Homo sapiens;
-
in 40 mM Tris pH 7.5, 20 mM MgCl2, 0.1 mg/ml bovine serum albumin, at 30°C
0.0096
5-(4-acetyl-5-methyl-1H-1,2,3-triazol-1-yl)-4-bromo-2-(pyrimidin-5-yl)pyridazin-3(2H)-one
Homo sapiens;
-
in 40 mM Tris pH 7.5, 20 mM MgCl2, 0.1 mg/ml bovine serum albumin, at 30°C
0.0026
5-(4-acetyl-5-methyl-1H-1,2,3-triazol-1-yl)-4-bromo-2-phenethylpyridazin-3(2H)-one
Homo sapiens;
-
in 40 mM Tris pH 7.5, 20 mM MgCl2, 0.1 mg/ml bovine serum albumin, at 30°C
0.0074
5-(4-acetyl-5-methyl-1H-1,2,3-triazol-1-yl)-4-bromo-2-phenylpyridazin-3(2H)-one
Homo sapiens;
-
in 40 mM Tris pH 7.5, 20 mM MgCl2, 0.1 mg/ml bovine serum albumin, at 30°C
0.0262
5-(4-acetyl-5-methyl-1H-1,2,3-triazol-1-yl)-4-chloro-2-phenylpyridazin-3(2H)-one
Homo sapiens;
-
in 40 mM Tris pH 7.5, 20 mM MgCl2, 0.1 mg/ml bovine serum albumin, at 30°C
1
5-(4-acetyl-5-methyl-1H-1,2,3-triazol-1-yl)-4-ethoxy-2-phenylpyridazin-3(2H)-one
Homo sapiens;
-
IC50 above 1.0 mM, in 40 mM Tris pH 7.5, 20 mM MgCl2, 0.1 mg/ml bovine serum albumin, at 30°C
0.013
5-(4-acetyl-5-methyl-1H-1,2,3-triazol-1-yl)-4-iodo-2-phenylpyridazin-3(2H)-one
Homo sapiens;
-
in 40 mM Tris pH 7.5, 20 mM MgCl2, 0.1 mg/ml bovine serum albumin, at 30°C
0.5
5-(4-acetyl-5-methyl-1H-1,2,3-triazol-1-yl)-4-isopropyl-2-phenylpyridazin-3(2H)-one
Homo sapiens;
-
IC50 above 0.5 mM, in 40 mM Tris pH 7.5, 20 mM MgCl2, 0.1 mg/ml bovine serum albumin, at 30°C
0.055
ethyl 1-(6-oxo-1-phenyl-5-(2-oxa-6-azaspiro[3.3]heptan-6-yl)-1,6-dihydropyridazin-4-yl)-1H-1,2,3-triazole-4-carboxylate
Homo sapiens;
-
in 40 mM Tris pH 7.5, 20 mM MgCl2, 0.1 mg/ml bovine serum albumin, at 30°C
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Abortion, Habitual
Acceleration of the glycolytic flux by steroid receptor coactivator-2 is essential for endometrial decidualization.
Acidosis
Characterization of human fructose-1,6-bisphosphatase in control and deficient tissues.
Acidosis
Fructose 1,6-bisphosphatase deficiency: enzyme and mutation analysis performed on calcitriol-stimulated monocytes with a note on long-term prognosis.
Acidosis
Fructose-1,6-bisphosphatase deficiency as a cause of recurrent hypoglycemia and metabolic acidosis: Clinical and molecular findings in Malaysian patients.
Acidosis
Intravenous glycerol therapy should not be used in patients with unrecognized fructose-1,6-bisphosphatase deficiency.
Acidosis, Lactic
Novel compound heterozygous mutations in the fructose-1,6-bisphosphatase gene cause hypoglycemia and lactic acidosis.
Acidosis, Lactic
Pitfall in the Diagnosis of Fructose-1,6-Bisphosphatase Deficiency: Difficulty in Detecting Glycerol-3-Phosphate with Solvent Extraction in Urinary GC/MS Analysis.
Acute Lung Injury
Blockage of glycolysis by targeting PFKFB3 alleviates sepsis-related acute lung injury via suppressing inflammation and apoptosis of alveolar epithelial cells.
Adenocarcinoma
Expression of PFKFB3 and Ki67 in lung adenocarcinomas and targeting PFKFB3 as a therapeutic strategy.
Adenocarcinoma
Insulin induces PFKFB3 gene expression in HT29 human colon adenocarcinoma cells.
Adenocarcinoma
Interleukin-6 stimulates aerobic glycolysis by regulating PFKFB3 at early stage of colorectal cancer.
Adenocarcinoma
Structure-based design of small-molecule ligands of phosphofructokinase-2 activating or inhibiting glycolysis.
Adenocarcinoma
The Role of CD44 in Glucose Metabolism in Prostatic Small Cell Neuroendocrine Carcinoma.
Adenocarcinoma of Lung
Expression of PFKFB3 and Ki67 in lung adenocarcinomas and targeting PFKFB3 as a therapeutic strategy.
Adenocarcinoma of Lung
Structure-based design of small-molecule ligands of phosphofructokinase-2 activating or inhibiting glycolysis.
Adenoma
Interleukin-6 stimulates aerobic glycolysis by regulating PFKFB3 at early stage of colorectal cancer.
Astrocytoma
6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB3) is up-regulated in high-grade astrocytomas.
Astrocytoma
The PFKFB3 splice variant UBI2K4 is down-regulated in high-grade astrocytomas and impedes the growth of U87 glioblastoma cells.
Brain Edema
Intravenous glycerol therapy should not be used in patients with unrecognized fructose-1,6-bisphosphatase deficiency.
Brain Ischemia
PFKFB3-mediated glycolysis is involved in reactive astrocyte proliferation after oxygen-glucose deprivation/reperfusion and is regulated by Cdh1.
Breast Neoplasms
Aberrant methylation of human L- and M-fructose 1,6-bisphosphatase genes in cancer.
Breast Neoplasms
AMPK and PFKFB3 mediate glycolysis and survival in response to mitophagy during mitotic arrest.
Breast Neoplasms
Estradiol Stimulates Glucose Metabolism via 6-Phosphofructo-2-kinase (PFKFB3).
Breast Neoplasms
Inhibition of 6-phosphofructo-2-kinase (PFKFB3) suppresses glucose metabolism and the growth of HER2+ breast cancer.
Breast Neoplasms
Mechanisms of regulation of PFKFB expression in pancreatic and gastric cancer cells.
Breast Neoplasms
Metabolic enzyme PFKFB4 activates transcriptional coactivator SRC-3 to drive breast cancer.
Breast Neoplasms
Non-canonical roles of PFKFB3 in regulation of cell cycle through binding to CDK4.
Breast Neoplasms
Overexpression of miR-206 suppresses glycolysis, proliferation and migration in breast cancer cells via PFKFB3 targeting.
Breast Neoplasms
PFKFB3 is involved in breast cancer proliferation, migration, invasion and angiogenesis.
Breast Neoplasms
PFKFB3 potentially contributes to paclitaxel resistance in breast cancer cells through TLR4 activation by stimulating lactate production.
Breast Neoplasms
Progestins activate 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3) in breast cancer cells.
Breast Neoplasms
Sonic hedgehog stimulates glycolysis and proliferation of breast cancer cells: Modulation of PFKFB3 activation.
Breast Neoplasms
Structure-based design of small-molecule ligands of phosphofructokinase-2 activating or inhibiting glycolysis.
Carcinogenesis
6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB3) is up-regulated in high-grade astrocytomas.
Carcinogenesis
Expression of PFKFB3 and Ki67 in lung adenocarcinomas and targeting PFKFB3 as a therapeutic strategy.
Carcinogenesis
PFKFB3 Control of Cancer Growth by Responding to Circadian Clock Outputs.
Carcinogenesis
Roles of PFKFB3 in cancer.
Carcinoma
6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase gene family overexpression in human lung tumor.
Carcinoma
Blockage of glycolysis by targeting PFKFB3 suppresses tumor growth and metastasis in head and neck squamous cell carcinoma.
Carcinoma
PFKFB4 as a prognostic marker in non-muscle-invasive bladder cancer.
Carcinoma
Phosphorylation of the 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatase/PFKFB3 family of glycolytic regulators in human cancer.
Carcinoma
The Role of CD44 in Glucose Metabolism in Prostatic Small Cell Neuroendocrine Carcinoma.
Carcinoma
TP53-inducible Glycolysis and Apoptosis Regulator (TIGAR) Metabolically Reprograms Carcinoma and Stromal Cells in Breast Cancer.
Carcinoma, Hepatocellular
Adenovirus-mediated overexpression of liver 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase in gluconeogenic rat hepatoma cells. Paradoxical effect on Fru-2,6-P2 levels.
Carcinoma, Hepatocellular
By inhibiting PFKFB3, aspirin overcomes sorafenib resistance in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Characterization of the human liver fructose-1,6-bisphosphatase gene promoter.
Carcinoma, Hepatocellular
Cloning and expression in Escherichia coli of a rat hepatoma cell cDNA coding for 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase.
Carcinoma, Hepatocellular
Coordinated Expression of 6-Phosphofructo-2-kinase/Fructose-2,6-bisphosphatase 4 and Heme Oxygenase 2: Evidence for a Regulatory Link between Glycolysis and Heme Catabolism.
Carcinoma, Hepatocellular
Expression and hypoxia-responsiveness of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 in mammary gland malignant cell lines.
Carcinoma, Hepatocellular
Expression of the liver 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase mRNA in FAO-1 cells.
Carcinoma, Hepatocellular
Fructose 2,6-bisphosphate and the control of glycolysis by growth factors, tumor promoters and oncogenes.
Carcinoma, Hepatocellular
Hormonal control of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase gene expression in rat hepatoma cells.
Carcinoma, Hepatocellular
Insulin inhibits glucocorticoid-induced stimulation of liver 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase gene transcription.
Carcinoma, Hepatocellular
MACC1 expression correlates with PFKFB2 and survival in hepatocellular carcinoma.
Carcinoma, Hepatocellular
PFKFB3 blockade inhibits hepatocellular carcinoma growth by impairing DNA repair through AKT.
Carcinoma, Hepatocellular
Phosphorylation of PPAR? at Ser84 promotes glycolysis and cell proliferation in hepatocellular carcinoma by targeting PFKFB4.
Carcinoma, Hepatocellular
Rat hepatoma (HTC) cell 6-phosphofructo-2-kinase differs from that in liver and can be separated from fructose-2,6-bisphosphatase.
Carcinoma, Non-Small-Cell Lung
Liposomes co-Loaded with 6-Phosphofructo-2-Kinase/Fructose-2, 6-Biphosphatase 3 (PFKFB3) shRNA Plasmid and Docetaxel for the Treatment of non-small Cell Lung Cancer.
Carcinoma, Small Cell
The Role of CD44 in Glucose Metabolism in Prostatic Small Cell Neuroendocrine Carcinoma.
Carcinoma, Squamous Cell
Blockage of glycolysis by targeting PFKFB3 suppresses tumor growth and metastasis in head and neck squamous cell carcinoma.
Clonorchiasis
Biochemical characterization and functional analysis of fructose-1,6-bisphosphatase from Clonorchis sinensis.
Colonic Neoplasms
Mechanisms of regulation of PFKFB expression in pancreatic and gastric cancer cells.
Colonic Neoplasms
Systematic Analysis of Gene Expression Alterations and Clinical Outcomes for Long-Chain Acyl-Coenzyme A Synthetase Family in Cancer.
Colorectal Neoplasms
Interleukin-6 stimulates aerobic glycolysis by regulating PFKFB3 at early stage of colorectal cancer.
Dehydration
Inhibition of photosynthesis and energy dissipation induced by water and high light stresses in rice.
Diabetes Mellitus
Cardiac Insulin Signaling Regulates Glycolysis Through Phosphofructokinase 2 Content and Activity.
Diabetes Mellitus
Insulin resistance: an additional risk factor in the pathogenesis of cardiovascular disease in type 2 diabetes.
Diabetes Mellitus
[Changes in the level of fructose-2,6-biphosphate in peripheral blood lymphocytes in patients with diabetes mellitus]
Diabetes Mellitus, Type 1
Cardiac Insulin Signaling Regulates Glycolysis Through Phosphofructokinase 2 Content and Activity.
Diabetes Mellitus, Type 1
Mononuclear and polymorphonuclear leukocytes show increased fructose-1,6-bisphosphatase activity in patients with type 1 diabetes mellitus.
Diabetes Mellitus, Type 2
A cis-eQTL in PFKFB2 is associated with diabetic nephropathy, adiposity and insulin secretion in American Indians.
Diabetes Mellitus, Type 2
Additive activation of glucokinase by the bifunctional enzyme 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase and the chemical activator LY2121260.
Diabetes Mellitus, Type 2
Fructose-1,6-bisphosphatase inhibitors. 1. Purine phosphonic acids as novel AMP mimics.
Diabetes Mellitus, Type 2
Fructose-1,6-bisphosphatase Inhibitors. 2. Design, synthesis, and structure-activity relationship of a series of phosphonic acid containing benzimidazoles that function as 5'-adenosinemonophosphate (AMP) mimics.
Diabetes Mellitus, Type 2
Fructose-1,6-bisphosphatase overexpression in pancreatic beta-cells results in reduced insulin secretion: a new mechanism for fat-induced impairment of beta-cell function.
Diabetes Mellitus, Type 2
Increased glucose production in mice overexpressing human fructose-1,6-bisphosphatase in the liver.
Diabetes Mellitus, Type 2
Inhibition of fructose 1,6-bisphosphatase reduces excessive endogenous glucose production and attenuates hyperglycemia in zucker diabetic Fatty rats.
Diabetes Mellitus, Type 2
MB06322 (CS-917): A potent and selective inhibitor of fructose 1,6-bisphosphatase for controlling gluconeogenesis in type 2 diabetes.
Diabetes Mellitus, Type 2
Structure-guided design of AMP mimics that inhibit fructose-1,6-bisphosphatase with high affinity and specificity.
Diabetic Nephropathies
A cis-eQTL in PFKFB2 is associated with diabetic nephropathy, adiposity and insulin secretion in American Indians.
Embolism
Interleukin-6 stimulates aerobic glycolysis by regulating PFKFB3 at early stage of colorectal cancer.
fructose-2,6-bisphosphate 2-phosphatase deficiency
A potential role for muscle in glucose homeostasis: in vivo kinetic studies in glycogen storage disease type 1a and fructose-1,6-bisphosphatase deficiency.
fructose-2,6-bisphosphate 2-phosphatase deficiency
Characterization of human fructose-1,6-bisphosphatase in control and deficient tissues.
fructose-2,6-bisphosphate 2-phosphatase deficiency
Clinical and Molecular Characterization of Patients with Fructose 1,6-Bisphosphatase Deficiency.
fructose-2,6-bisphosphate 2-phosphatase deficiency
Diagnosis of fructose-1,6-bisphosphatase deficiency using cultured lymphocyte fraction: a secure and noninvasive alternative to liver biopsy.
fructose-2,6-bisphosphate 2-phosphatase deficiency
Fructose 1,6-bisphosphatase deficiency: clinical, biochemical and genetic features in French patients.
fructose-2,6-bisphosphate 2-phosphatase deficiency
Fructose 1,6-bisphosphatase deficiency: enzyme and mutation analysis performed on calcitriol-stimulated monocytes with a note on long-term prognosis.
fructose-2,6-bisphosphate 2-phosphatase deficiency
Fructose-1,6-bisphosphatase deficiency as a cause of recurrent hypoglycemia and metabolic acidosis: Clinical and molecular findings in Malaysian patients.
fructose-2,6-bisphosphate 2-phosphatase deficiency
Fructose-1,6-bisphosphatase deficiency caused by a novel homozygous Alu element insertion in the FBP1 gene and delayed diagnosis.
fructose-2,6-bisphosphate 2-phosphatase deficiency
Fructose-1,6-Bisphosphatase Deficiency: A Case of a Successful Pregnancy by Closely Monitoring Metabolic Control.
fructose-2,6-bisphosphate 2-phosphatase deficiency
Genetic analysis of fructose-1,6-bisphosphatase (FBPase) deficiency in nine consanguineous Pakistani families.
fructose-2,6-bisphosphate 2-phosphatase deficiency
Identification of a response element for vitamin D3 and retinoic acid in the promoter region of the human fructose-1,6-bisphosphatase gene.
fructose-2,6-bisphosphate 2-phosphatase deficiency
Identification of genetic mutations in Japanese patients with fructose-1,6-bisphosphatase deficiency.
fructose-2,6-bisphosphate 2-phosphatase deficiency
International practices in the dietary management of fructose 1-6 biphosphatase deficiency.
fructose-2,6-bisphosphate 2-phosphatase deficiency
Intravenous glycerol therapy should not be used in patients with unrecognized fructose-1,6-bisphosphatase deficiency.
fructose-2,6-bisphosphate 2-phosphatase deficiency
Novel compound heterozygous mutations in the fructose-1,6-bisphosphatase gene cause hypoglycemia and lactic acidosis.
fructose-2,6-bisphosphate 2-phosphatase deficiency
Novel Fructose-1,6-bisphosphatase Gene Mutation in Two Siblings.
fructose-2,6-bisphosphate 2-phosphatase deficiency
Novel mutations in patients with fructose-1,6-bisphosphatase deficiency.
fructose-2,6-bisphosphate 2-phosphatase deficiency
Phosphofructokinase deficiency impairs ATP generation, autophagy, and redox balance in rheumatoid arthritis T cells.
fructose-2,6-bisphosphate 2-phosphatase deficiency
Pitfall in the Diagnosis of Fructose-1,6-Bisphosphatase Deficiency: Difficulty in Detecting Glycerol-3-Phosphate with Solvent Extraction in Urinary GC/MS Analysis.
fructose-2,6-bisphosphate 2-phosphatase deficiency
Role of PFKFB3-driven glycolysis in vessel sprouting.
fructose-2,6-bisphosphate 2-phosphatase deficiency
Three successful pregnancies through dietary management of fructose-1,6-bisphosphatase deficiency.
fructose-2,6-bisphosphate 2-phosphatase deficiency
Two newly identified genomic mutations in a Japanese female patient with fructose-1,6-bisphosphatase (FBPase) deficiency.
Glioblastoma
6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB3) is up-regulated in high-grade astrocytomas.
Glioblastoma
LOH on 10p14-p15 targets the PFKFB3 gene locus in human glioblastomas.
Glioblastoma
RNAi screening in glioma stem-like cells identifies PFKFB4 as a key molecule important for cancer cell survival.
Glioblastoma
TGF-?1 targets Smad, p38 MAPK, and PI3K/Akt signaling pathways to induce PFKFB3 gene expression and glycolysis in glioblastoma cells.
Glioblastoma
The PFKFB3 splice variant UBI2K4 is down-regulated in high-grade astrocytomas and impedes the growth of U87 glioblastoma cells.
Glioma
RNAi screening in glioma stem-like cells identifies PFKFB4 as a key molecule important for cancer cell survival.
Glioma
TGF-?1 targets Smad, p38 MAPK, and PI3K/Akt signaling pathways to induce PFKFB3 gene expression and glycolysis in glioblastoma cells.
Glioma
[EXPRESSION OF PFKFB, HK2, NAMPT, TSPAN13 AND HSPB8 GENES IN PEDIATRIC GLIOMA].
Glucose Intolerance
[EXPRESSION OF GENES, WHICH CONTROL GLUCOSE METABOLISM, IN BLOOD CELLS OF THE OBESE BOYS WITH INSULIN RESISTANCE].
Hyperglycemia
CS-917, a fructose 1,6-bisphosphatase inhibitor, improves postprandial hyperglycemia after meal loading in non-obese type 2 diabetic Goto-Kakizaki rats.
Hyperglycemia
Nuclear accumulation of fructose 1,6-bisphosphatase is impaired in diabetic rat liver.
Hypoglycemia
Fructose 1,6-bisphosphatase deficiency: enzyme and mutation analysis performed on calcitriol-stimulated monocytes with a note on long-term prognosis.
Hypoglycemia
Fructose-1,6-bisphosphatase deficiency as a cause of recurrent hypoglycemia and metabolic acidosis: Clinical and molecular findings in Malaysian patients.
Hypoglycemia
Fructose-1,6-Bisphosphatase Deficiency: A Case of a Successful Pregnancy by Closely Monitoring Metabolic Control.
Hypoglycemia
Intravenous glycerol therapy should not be used in patients with unrecognized fructose-1,6-bisphosphatase deficiency.
Hypoglycemia
Muscle fructose-2,6-bisphosphate and glucose-1,6-bisphosphate during insulin-induced hypoglycemia.
Hypoglycemia
Novel compound heterozygous mutations in the fructose-1,6-bisphosphatase gene cause hypoglycemia and lactic acidosis.
Hypoglycemia
Pitfall in the Diagnosis of Fructose-1,6-Bisphosphatase Deficiency: Difficulty in Detecting Glycerol-3-Phosphate with Solvent Extraction in Urinary GC/MS Analysis.
Hypoglycemia
Role of epinephrine during insulin-induced hypoglycemia in fasted rats.
Hypotension
Alterations in hepatic 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase and glucose-6-phosphatase gene expression after hemorrhagic hypotension and resuscitation.
Idiopathic Pulmonary Fibrosis
Glycolytic Reprogramming in Myofibroblast Differentiation and Lung Fibrosis.
Infection
Fructose 1,6-bisphosphatase deficiency: enzyme and mutation analysis performed on calcitriol-stimulated monocytes with a note on long-term prognosis.
Infertility
Acceleration of the glycolytic flux by steroid receptor coactivator-2 is essential for endometrial decidualization.
Insulin Resistance
Cardiac expression of kinase-deficient 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase inhibits glycolysis, promotes hypertrophy, impairs myocyte function, and reduces insulin sensitivity.
Insulin Resistance
Fructose-1, 6-bisphosphatase inhibitors for reducing excessive endogenous glucose production in type 2 diabetes.
Insulin Resistance
Jejunal gluconeogenesis associated with insulin resistance level and its evolution after Roux-en-Y gastric bypass.
Insulin Resistance
Potential effect of exercise in ameliorating insulin resistance at transcriptome level.
Insulin Resistance
Regulation of hepatic gluconeogenesis and glycogenolysis by phosphorylated glycerol and glycolytic intermediates in diabetic and control Chinese hamsters.
Insulin Resistance
[EXPRESSION OF GENES, WHICH CONTROL GLUCOSE METABOLISM, IN BLOOD CELLS OF THE OBESE BOYS WITH INSULIN RESISTANCE].
Ketosis
Fructose 1,6-bisphosphatase deficiency: enzyme and mutation analysis performed on calcitriol-stimulated monocytes with a note on long-term prognosis.
Ketosis
Pitfall in the Diagnosis of Fructose-1,6-Bisphosphatase Deficiency: Difficulty in Detecting Glycerol-3-Phosphate with Solvent Extraction in Urinary GC/MS Analysis.
Leukemia
6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase and tumor cell glycolysis.
Leukemia
TIGAR cooperated with glycolysis to inhibit the apoptosis of leukemia cells and associated with poor prognosis in patients with cytogenetically normal acute myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Targeting PFKFB3 sensitizes chronic myelogenous leukemia cells to tyrosine kinase inhibitor.
Leukemia, Myeloid, Acute
mTOR up-regulation of PFKFB3 is essential for acute myeloid leukemia cell survival.
Lung Neoplasms
6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase gene family overexpression in human lung tumor.
Lung Neoplasms
Cell cycle-dependent expression and subcellular localization of fructose 1,6-bisphosphatase.
Lung Neoplasms
Etk Interaction with PFKFB4 Modulates Chemoresistance of Small-cell Lung Cancer by Regulating Autophagy.
Lung Neoplasms
Liposomes co-Loaded with 6-Phosphofructo-2-Kinase/Fructose-2, 6-Biphosphatase 3 (PFKFB3) shRNA Plasmid and Docetaxel for the Treatment of non-small Cell Lung Cancer.
Lung Neoplasms
Mechanisms of regulation of PFKFB expression in pancreatic and gastric cancer cells.
Lung Neoplasms
Systematic Analysis of Gene Expression Alterations and Clinical Outcomes for Long-Chain Acyl-Coenzyme A Synthetase Family in Cancer.
Melanoma
RSK Regulates PFK-2 Activity to Promote Metabolic Rewiring in Melanoma.
Melanoma
Splice isoform of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-4: expression and hypoxic regulation.
Nasopharyngeal Carcinoma
PFKFB3 promotes proliferation, migration and angiogenesis in nasopharyngeal carcinoma.
Neoplasm Metastasis
Angiogenesis revisited from a metabolic perspective: role and therapeutic implications of endothelial cell metabolism.
Neoplasm Metastasis
Blockage of glycolysis by targeting PFKFB3 suppresses tumor growth and metastasis in head and neck squamous cell carcinoma.
Neoplasm Metastasis
Endothelial cell metabolism: an update anno 2017.
Neoplasm Metastasis
Estradiol Stimulates Glucose Metabolism via 6-Phosphofructo-2-kinase (PFKFB3).
Neoplasm Metastasis
Expression of PFKFB3 and Ki67 in lung adenocarcinomas and targeting PFKFB3 as a therapeutic strategy.
Neoplasm Metastasis
Inhibition of the Glycolytic Activator PFKFB3 in Endothelium Induces Tumor Vessel Normalization, Impairs Metastasis, and Improves Chemotherapy.
Neoplasm Metastasis
Interleukin-6 stimulates aerobic glycolysis by regulating PFKFB3 at early stage of colorectal cancer.
Neoplasm Metastasis
PFKFB3 promotes proliferation, migration and angiogenesis in nasopharyngeal carcinoma.
Neoplasm Metastasis
PFKFB3 was overexpressed in gastric cancer patients and promoted the proliferation and migration of gastric cancer cells.
Neoplasms
6-Phosphofructo-2-kinase (pfkfb3) gene promoter contains hypoxia-inducible factor-1 binding sites necessary for transactivation in response to hypoxia.
Neoplasms
6-Phosphofructo-2-kinase (PFKFB3) promotes cell cycle progression and suppresses apoptosis via Cdk1-mediated phosphorylation of p27.
Neoplasms
6-Phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 is essential for p53-null cancer cells.
Neoplasms
6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB3) is up-regulated in high-grade astrocytomas.
Neoplasms
6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase and tumor cell glycolysis.
Neoplasms
6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase gene family overexpression in human lung tumor.
Neoplasms
6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase isoform 3 spatially mediates autophagy through the AMPK signaling pathway.
Neoplasms
A High-Throughput Screening Triage Workflow to Authenticate a Novel Series of PFKFB3 Inhibitors.
Neoplasms
Aberrant methylation of human L- and M-fructose 1,6-bisphosphatase genes in cancer.
Neoplasms
Acetylation accumulates PFKFB3 in cytoplasm to promote glycolysis and protects cells from cisplatin-induced apoptosis.
Neoplasms
Adapting glycolysis to cancer cell proliferation: the MAPK pathway focuses on PFKFB3.
Neoplasms
Akt mediates TIGAR induction in HeLa cells following PFKFB3 inhibition.
Neoplasms
An inducible gene product for 6-phosphofructo-2-kinase with an AU-rich instability element: role in tumor cell glycolysis and the Warburg effect.
Neoplasms
Angiogenesis revisited from a metabolic perspective: role and therapeutic implications of endothelial cell metabolism.
Neoplasms
Antiproliferative cyclodepsipeptides from the marine actinomycete Streptomyces sp. P11-23B downregulating the tumor metabolic enzymes of glycolysis, glutaminolysis, and lipogenesis.
Neoplasms
Balancing glycolytic flux: the role of 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatases in cancer metabolism.
Neoplasms
Blockage of glycolysis by targeting PFKFB3 suppresses tumor growth and metastasis in head and neck squamous cell carcinoma.
Neoplasms
Cancer cell metabolism: there is no ROS for the weary.
Neoplasms
Characterization of a new liver- and kidney-specific pfkfb3 isozyme that is downregulated by cell proliferation and dedifferentiation.
Neoplasms
Cloning and chromosomal characterization of the 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 gene (PFKFB3, iPFK2).
Neoplasms
CO-CBS-H2 S Axis: From Vascular Mediator to Cancer Regulator.
Neoplasms
Control of Glycolytic Flux by AMP-Activated Protein Kinase in Tumor Cells Adapted to Low pH.
Neoplasms
Crystal structure of the hypoxia-inducible form of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB3): a possible new target for cancer therapy.
Neoplasms
Endothelial cell metabolism: an update anno 2017.
Neoplasms
Expression and hypoxia-responsiveness of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 in mammary gland malignant cell lines.
Neoplasms
Expression of 6-phosphofructo-2-kinase/ fructose-2,6-bisphosphatase-3 and VEGF mRNA in rat liver, lung and heart: effect of methyl tertbutyl ether.
Neoplasms
Expression of PFKFB3 and Ki67 in lung adenocarcinomas and targeting PFKFB3 as a therapeutic strategy.
Neoplasms
Fructose 2,6-bisphosphate metabolism in Ehrlich ascites tumour cells.
Neoplasms
Fructose-2,6-bisphosphate synthesis by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 (PFKFB4) is required for the glycolytic response to hypoxia and tumor growth.
Neoplasms
Functional metabolic screen identifies 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 as an important regulator of prostate cancer cell survival.
Neoplasms
Genetic alteration in phosphofructokinase family promotes growth of muscle-invasive bladder cancer.
Neoplasms
Glucose deprivation increases mRNA stability of vascular endothelial growth factor through activation of AMP-activated protein kinase in DU145 prostate carcinoma.
Neoplasms
HIF-1? activates hypoxia-induced PFKFB4 expression in human bladder cancer cells.
Neoplasms
High expression of inducible 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (iPFK-2; PFKFB3) in human cancers.
Neoplasms
Hypoxia induces transcription of 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase-4 gene via hypoxia-inducible factor-1alpha activation.
Neoplasms
Hypoxia, glucose metabolism and the Warburg's effect.
Neoplasms
Hypoxic regulation of PFKFB-3 and PFKFB-4 gene expression in gastric and pancreatic cancer cell lines and expression of PFKFB genes in gastric cancers.
Neoplasms
Identification and characterization of the hypoxia-responsive element of the human placental 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase gene.
Neoplasms
Identification of TP53-induced glycolysis and apoptosis regulator (TIGAR) as the phosphoglycolate-independent 2,3-bisphosphoglycerate phosphatase.
Neoplasms
Inhibition of 6-phosphofructo-2-kinase (PFKFB3) induces autophagy as a survival mechanism.
Neoplasms
Inhibition of Growth by Combined Treatment with Inhibitors of Lactate Dehydrogenase and either Phenformin or Inhibitors of 6-Phosphofructo-2-kinase/Fructose-2,6-bisphosphatase 3.
Neoplasms
Inhibition of the Glycolytic Activator PFKFB3 in Endothelium Induces Tumor Vessel Normalization, Impairs Metastasis, and Improves Chemotherapy.
Neoplasms
Interleukin-6 stimulates aerobic glycolysis by regulating PFKFB3 at early stage of colorectal cancer.
Neoplasms
Investigating combinatorial approaches in virtual screening on human inducible 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB3): A case study for small molecule kinases.
Neoplasms
Kinome Screen Identifies PFKFB3 and Glucose Metabolism as Important Regulators of the Insulin/Insulin-like Growth Factor (IGF)-1 Signaling Pathway.
Neoplasms
LOH on 10p14-p15 targets the PFKFB3 gene locus in human glioblastomas.
Neoplasms
Mechanisms of regulation of PFKFB expression in pancreatic and gastric cancer cells.
Neoplasms
MicroRNA-26b inhibits osteosarcoma cell migration and invasion by down-regulating PFKFB3 expression.
Neoplasms
miR-139-5p inhibits aerobic glycolysis, cell proliferation, migration, and invasion in hepatocellular carcinoma via a reciprocal regulatory interaction with ETS1.
Neoplasms
Monocyte fructose 1,6-bisphosphatase and cytidine deaminase enzyme activities: potential pharmacodynamic measures of calcitriol effects in cancer patients.
Neoplasms
Nuclear targeting of 6-phosphofructo-2-kinase (PFKFB3) increases proliferation via cyclin-dependent kinases.
Neoplasms
Overexpression of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-4 in the human breast and colon malignant tumors.
Neoplasms
Overexpression of ubiquitous 6-phosphofructo-2-kinase in the liver of transgenic mice results in weight gain.
Neoplasms
p53 coordinates DNA repair with nucleotide synthesis by suppressing PFKFB3 expression and promoting the pentose phosphate pathway.
Neoplasms
PFK15, a Small Molecule Inhibitor of PFKFB3, Induces Cell Cycle Arrest, Apoptosis and Inhibits Invasion in Gastric Cancer.
Neoplasms
Pfkfb (6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase) isoforms display a tissue-specific and dynamic expression during Xenopus laevis development.
Neoplasms
PFKFB3 activation in cancer cells by the p38/MK2 pathway in response to stress stimuli.
Neoplasms
PFKFB3 blockade inhibits hepatocellular carcinoma growth by impairing DNA repair through AKT.
Neoplasms
PFKFB3 Control of Cancer Growth by Responding to Circadian Clock Outputs.
Neoplasms
PFKFB3 is involved in breast cancer proliferation, migration, invasion and angiogenesis.
Neoplasms
PFKFB3 modulates glycolytic metabolism and alleviates endoplasmic reticulum stress in human osteoarthritis cartilage.
Neoplasms
PFKFB3 promotes proliferation, migration and angiogenesis in nasopharyngeal carcinoma.
Neoplasms
PFKFB3 regulates oxidative stress homeostasis via its S-glutathionylation in cancer.
Neoplasms
PFKFB4 as a prognostic marker in non-muscle-invasive bladder cancer.
Neoplasms
Phosphorylation of the 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatase/PFKFB3 family of glycolytic regulators in human cancer.
Neoplasms
Ras transformation requires metabolic control by 6-phosphofructo-2-kinase.
Neoplasms
Reduced methylation of PFKFB3 in cancer cells shunts glucose towards the pentose phosphate pathway.
Neoplasms
RNAi screening in glioma stem-like cells identifies PFKFB4 as a key molecule important for cancer cell survival.
Neoplasms
Roles of PFKFB3 in cancer.
Neoplasms
Structure-based development of small molecule PFKFB3 inhibitors: a framework for potential cancer therapeutic agents targeting the Warburg effect.
Neoplasms
Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer.
Neoplasms
Targeting FBPase is an emerging novel approach for cancer therapy.
Neoplasms
Targeting of MCT1 and PFKFB3 influences cell proliferation and apoptosis in bladder cancer by altering the tumor microenvironment.
Neoplasms
Targeting PFKFB3 in the Endothelium for Cancer Therapy.
Neoplasms
Targeting the sugar metabolism of tumors with a first-in-class 6-phosphofructo-2-kinase (PFKFB4) inhibitor.
Neoplasms
Targeting the Warburg Effect in cancer; relationships for 2-arylpyridazinones as inhibitors of the key glycolytic enzyme 6-phosphofructo-2-kinase/2,6-bisphosphatase 3 (PFKFB3).
Neoplasms
The expression pattern of PFKFB3 enzyme distinguishes between induced-pluripotent stem cells and cancer stem cells.
Neoplasms
The JAK2V617F oncogene requires expression of inducible phosphofructokinase/fructose-bisphosphatase 3 for cell growth and increased metabolic activity.
Neoplasms
The molecular basis of targeting PFKFB3 as a therapeutic strategy against cancer.
Neoplasms
The PFKFB3 splice variant UBI2K4 is down-regulated in high-grade astrocytomas and impedes the growth of U87 glioblastoma cells.
Neoplasms
The role of 6-phosphofructo-2-kinase (PFK-2)/fructose 2,6-bisphosphatase (FBPase-2) in metabolic reprogramming of cancer cells.
Neoplasms
TIGAR's promiscuity.
Neoplasms
To PFKFB3 or Not to PFKFB3, That Is the Question.
Neoplasms
Tumor vessel disintegration by maximum tolerable PFKFB3 blockade.
Neoplasms
[Antineoplastic properties of extracellular fructoso-1,6-bisphosphatase of Bacillus subtilis 668 and preparation isolated from cultural liquids of Bacillus subtilis 7025]
Neoplasms
[EXPRESSION OF PFKFB, HK2, NAMPT, TSPAN13 AND HSPB8 GENES IN PEDIATRIC GLIOMA].
Obesity
Association analysis of positional obesity candidate genes based on integrated data from transcriptomics and linkage analysis.
Obesity
[EXPRESSION OF GENES, WHICH CONTROL GLUCOSE METABOLISM, IN BLOOD CELLS OF THE OBESE BOYS WITH INSULIN RESISTANCE].
Obesity, Morbid
Association analysis of positional obesity candidate genes based on integrated data from transcriptomics and linkage analysis.
Osteoarthritis
Inhibition of 6-phosphofructo-2-kinase suppresses fibroblast-like synoviocytes-mediated synovial inflammation and joint destruction in rheumatoid arthritis.
Osteoarthritis
PFKFB3 modulates glycolytic metabolism and alleviates endoplasmic reticulum stress in human osteoarthritis cartilage.
Osteosarcoma
MicroRNA-26b inhibits osteosarcoma cell migration and invasion by down-regulating PFKFB3 expression.
Osteosarcoma
miR-26b inhibits proliferation, migration, invasion and apoptosis induction via the downregulation of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 driven glycolysis in osteosarcoma cells.
Ovarian Neoplasms
A comparative analysis of inhibitors of the glycolysis pathway in breast and ovarian cancer cell line models.
Ovarian Neoplasms
Loss of PFKFB4 induces cell death in mitotically arrested ovarian cancer cells.
Pancreatic Neoplasms
Hypoxic regulation of PFKFB-3 and PFKFB-4 gene expression in gastric and pancreatic cancer cell lines and expression of PFKFB genes in gastric cancers.
Pancreatic Neoplasms
Mechanisms of regulation of PFKFB expression in pancreatic and gastric cancer cells.
Prostatic Neoplasms
Androgen stimulates glycolysis for de novo lipid synthesis by increasing the activities of hexokinase 2 and 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 2 in prostate cancer cells.
Prostatic Neoplasms
CD44 regulates prostate cancer proliferation, invasion and migration via PDK1 and PFKFB4.
Prostatic Neoplasms
Functional metabolic screen identifies 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 as an important regulator of prostate cancer cell survival.
Prostatic Neoplasms
Hypoxia induces transcription of 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase-4 gene via hypoxia-inducible factor-1alpha activation.
Prostatic Neoplasms
Identification of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase as a novel autophagy regulator by high content shRNA screening.
Respiratory Syncytial Virus Infections
PFKFB3-Driven Macrophage Glycolytic Metabolism Is a Crucial Component of Innate Antiviral Defense.
Sarcoma 37
[Antineoplastic properties of extracellular fructoso-1,6-bisphosphatase of Bacillus subtilis 668 and preparation isolated from cultural liquids of Bacillus subtilis 7025]
Sarcoma, Avian
Activation of 6-phosphofructo-2-kinase by pp60v-src is an indirect effect.
Squamous Cell Carcinoma of Head and Neck
Blockage of glycolysis by targeting PFKFB3 suppresses tumor growth and metastasis in head and neck squamous cell carcinoma.
Starvation
Age-dependent glycolysis and gluconeogenesis enzyme activities in starved-refed rats.
Starvation
Changes in rat hepatic fructose 2,6-bisphosphate and 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatase activity during three days of consumption of a high protein diet or starvation.
Starvation
Comparison between starvation and consumption of a high protein diet: plasma insulin and glucagon and hepatic activities of gluconeogenic enzymes during the first 24 hours.
Starvation
Degradation of the gluconeogenic enzymes fructose-1,6-bisphosphatase and malate dehydrogenase is mediated by distinct proteolytic pathways and signaling events.
Starvation
Effect of starvation on gene expression of regulatory enzymes of glycolysis/gluconeogenesis in genetically obese (fa/fa) Zucker rats.
Starvation
Induction of rat liver 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase mRNA by refeeding and insulin.
Starvation
Inhibition of 6-phosphofructo-2-kinase (PFKFB3) induces autophagy as a survival mechanism.
Starvation
Predominant periportal expression of the fructose 1,6-bisphosphatase gene in rat liver: dynamics during the daily feeding rhythm and starvation-refeeding cycle.
Starvation
The TOR complex 1 is distributed in endosomes and in retrograde vesicles that form from the vacuole membrane and plays an important role in the vacuole import and degradation pathway.
Starvation
Vps34p is required for the decline of extracellular fructose-1,6-bisphosphtase in the vacuole import and degradation pathway.
Stomach Neoplasms
Hypoxic regulation of PFKFB-3 and PFKFB-4 gene expression in gastric and pancreatic cancer cell lines and expression of PFKFB genes in gastric cancers.
Stomach Neoplasms
Mechanisms of regulation of PFKFB expression in pancreatic and gastric cancer cells.
Stomach Neoplasms
PFK15, a Small Molecule Inhibitor of PFKFB3, Induces Cell Cycle Arrest, Apoptosis and Inhibits Invasion in Gastric Cancer.
Stomach Neoplasms
PFKFB3 was overexpressed in gastric cancer patients and promoted the proliferation and migration of gastric cancer cells.
Tongue Neoplasms
PFKFB3 Control of Cancer Growth by Responding to Circadian Clock Outputs.
Tuberculosis
The Mycobacterium tuberculosis Rv1099c gene encodes a GlpX-like class II fructose 1,6-bisphosphatase.
Urinary Bladder Neoplasms
Genetic alteration in phosphofructokinase family promotes growth of muscle-invasive bladder cancer.
Urinary Bladder Neoplasms
HIF-1? activates hypoxia-induced PFKFB4 expression in human bladder cancer cells.
Urinary Bladder Neoplasms
PFKFB4 as a prognostic marker in non-muscle-invasive bladder cancer.
Urinary Bladder Neoplasms
Targeting of MCT1 and PFKFB3 influences cell proliferation and apoptosis in bladder cancer by altering the tumor microenvironment.
Virus Diseases
PFKFB3-Driven Macrophage Glycolytic Metabolism Is a Crucial Component of Innate Antiviral Defense.
Vitamin A Deficiency
Vitamin A regulates genes involved in hepatic gluconeogenesis in mice: phosphoenolpyruvate carboxykinase, fructose-1,6-bisphosphatase and 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Algaier, J.; Uyeda, K.
Molecular cloning, sequence analysis, and expression of a human liver cDNA coding for fructose-6-P,2-kinase:fructose-2,6-bisphosphatase
Biochem. Biophys. Res. Commun.
153
328-333
1988
Homo sapiens
brenda
Sakakibara, R.; Uemura, M.; Hirata, T.; Okamura, N.; Kato, M.
Human placental fructose-6-phosphate,2-kinase/fructose-2,6-bisphosphatase: its isozymic form, expression and characterization
Biosci. Biotechnol. Biochem.
61
1949-1952
1997
Homo sapiens
brenda
Sakakibara, R.; Kato, M.; Okamura, N.; Nakagawa, T.; Komada, Y.; Tominaga, N.; Shimojo, M.; Fukasawa, M.
Characterization of a human placental fructose-6-phosphate,2-kinase fructose-2,6-bisphosphatase
J. Biochem.
122
122-128
1997
Homo sapiens
brenda
Lee, Y.H.; Li, Y.; Uyeda, K.; Hasemann, C.A.
Tissue-specific structure/function differentiation of the liver isoform of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase
J. Biol. Chem.
278
523-530
2003
Homo sapiens, Homo sapiens (P16118)
brenda
Kessler, R.; Eschrich, K.
Splice isoforms of ubiquitous 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase in human brain
Brain Res.
87
190-195
2001
Homo sapiens, Homo sapiens (Q9BQU3)
brenda
Okar, D.A.; Wu, C.; Lange, A.J.
Regulation of the regulatory enzyme, 6-phosphofructo-2-kinase/fructose-2 6-biphosphatase
Adv. Enzyme Regul.
44
123-154
2004
Homo sapiens, Rattus norvegicus
brenda
Rider, M.H.; Bertrand, L.; Vertommen, D.; Michels, P.A.; Rousseau, G.G.; Hue, L.
6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase: head-to-head with a bifunctional enzyme that controls glycolysis
Biochem. J.
381
561-579
2004
Arabidopsis thaliana (Q9MB58), Bos taurus (P26285), Bos taurus (P49872), Bos taurus (Q28901), Desulfovibrio desulfuricans, Drosophila melanogaster (Q9VWH7), Homo sapiens (O60825), Homo sapiens (P16118), Homo sapiens (Q16875), Homo sapiens (Q16877), Leishmania major, Mus musculus (P70265), Mus musculus (Q9ESY2), Rattus norvegicus (O35552), Rattus norvegicus (P07953), Rattus norvegicus (P25114), Rattus norvegicus (Q9JJH5), Schizosaccharomyces pombe
brenda
Minchenko, O.H.; Ochiai, A.; Opentanova, I.L.; Ogura, T.; Minchenko, D.O.; Caro, J.; Komisarenko, S.V.; Esumi, H.
Overexpression of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-4 in the human breast and colon malignant tumors
Biochimie
87
1005-1010
2005
Homo sapiens
brenda
Atsumi, T.; Nishio, T.; Niwa, H.; Takeuchi, J.; Bando, H.; Shimizu, C.; Yoshioka, N.; Bucala, R.; Koike, T.
Expression of inducible 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase/PFKFB3 isoforms in adipocytes and their potential role in glycolytic regulation
Diabetes
54
3349-3357
2005
Homo sapiens, Mus musculus
brenda
Kim, S.G.; Manes, N.P.; El-Maghrabi, M.R.; Lee, Y.H.
Crystal structure of the hypoxia-inducible form of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB3): a possible new target for cancer therapy
J. Biol. Chem.
281
2939-2944
2006
Homo sapiens, Homo sapiens (P16118)
brenda
Minchenko, O.H.; Ogura, T.; Opentanova, I.L.; Minchenko, D.O.; Esumi, H.
Splice isoform of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-4: expression and hypoxic regulation
Mol. Cell. Biochem.
280
227-234
2005
Homo sapiens (Q16877)
brenda
Chesney, J.
6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase and tumor cell glycolysis
Curr. Opin. Clin. Nutr. Metab. Care
9
535-539
2006
Homo sapiens
brenda
Arden, C.; Hampson, L.J.; Huang, G.C.; Shaw, J.A.; Aldibbiat, A.; Holliman, G.; Manas, D.; Khan, S.; Lange, A.J.; Agius, L.
A role for PFK-2/FBPase-2 as distinct from fructose 2,6-bisphosphate in regulation of insulin secretion in pancreatic beta-cells
Biochem. J.
411
41-51
2007
Homo sapiens, Mus musculus, Mus musculus C57/BL6, Rattus norvegicus, Rattus norvegicus Wistar
brenda
Kim, S.G.; Cavalier, M.; El-Maghrabi, M.R.; Lee, Y.H.
A direct substrate-substrate interaction found in the kinase domain of the bifunctional enzyme, 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase
J. Mol. Biol.
370
14-26
2007
Homo sapiens
brenda
Shaikh, M.S.; Mittal, A.; Bharatam, P.V.
Design of fructose-2,6-bisphosphatase inhibitors: A novel virtual screening approach
J. Mol. Graph. Model.
26
900-906
2008
Homo sapiens
brenda
Kessler, R.; Bleichert, F.; Warnke, J.P.; Eschrich, K.
6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB3) is up-regulated in high-grade astrocytomas
J. Neurooncol.
86
257-264
2008
Homo sapiens
brenda
Myers, R.W.; Baginsky, W.F.; Gattermeir, D.J.; Geissler, W.M.; Harris, G.
Enzymatic preparation of high-specific-activity beta-D-[6,6-3H]fructose-2,6-bisphosphate: application to a sensitive assay for fructose-2,6-bisphosphatase
Anal. Biochem.
406
97-104
2010
Homo sapiens
brenda
Crochet, R.B.; Cavalier, M.C.; Seo, M.; Kim, J.D.; Yim, Y.S.; Park, S.J.; Lee, Y.H.
Investigating: a case study for small molecule kinases
Anal. Biochem.
418
143-148
2011
Homo sapiens
brenda
Moon, J.S.; Jin, W.J.; Kwak, J.H.; Kim, H.J.; Yun, M.J.; Kim, J.W.; Park, S.W.; Kim, K.S.
Androgen stimulates glycolysis for de novo lipid synthesis by increasing the activities of hexokinase 2 and 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 2 in prostate cancer cells
Biochem. J.
433
225-233
2011
Homo sapiens
brenda
Brooke, D.G.; van Dam, E.M.; Watts, C.K.; Khoury, A.; Dziadek, M.A.; Brooks, H.; Graham, L.J.; Flanagan, J.U.; Denny, W.A.
Targeting the Warburg Effect in cancer; relationships for 2-arylpyridazinones as inhibitors of the key glycolytic enzyme 6-phosphofructo-2-kinase/2,6-bisphosphatase 3 (PFKFB3)
Bioorg. Med. Chem.
22
1029-1039
2014
Homo sapiens
brenda
Ros, S.; Schulze, A.
Balancing glycolytic flux: the role of 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatases in cancer metabolism
Cancer Metab.
1
8-8
2013
Homo sapiens
brenda
Novellasdemunt, L.; Tato, I.; Navarro-Sabate, A.; Ruiz-Meana, M.; Mendez-Lucas, A.; Perales, J.C.; Garcia-Dorado, D.; Ventura, F.; Bartrons, R.; Rosa, J.L.
Akt-dependent activation of the heart 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB2) isoenzyme by amino acids
J. Biol. Chem.
288
10640-10651
2013
Homo sapiens, Homo sapiens (O60825), Rattus norvegicus
brenda
Chesney, J.; Clark, J.; Klarer, A.C.; Imbert-Fernandez, Y.; Lane, A.N.; Telang, S.
Fructose-2,6-bisphosphate synthesis by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 (PFKFB4) is required for the glycolytic response to hypoxia and tumor growth
Oncotarget
5
6670-6686
2014
Homo sapiens, Homo sapiens (Q16877)
brenda
Cavalier, M.C.; Kim, S.G.; Neau, D.; Lee, Y.H.
Molecular basis of the fructose-2,6-bisphosphatase reaction of PFKFB3: transition state and the C-terminal function
Proteins
80
1143-1153
2012
Homo sapiens, Homo sapiens (Q16875)
brenda